Current position:News > News
News
TSHR: The Core Target in Thyroid Metabolic Regulation and Disease Therapy
The thyroid-stimulating hormone receptor (TSHR) is emerging as a key target in next-generation thyroid and autoimmune disease treatments. Once limited to hormone regulation, TSHR therapies now combine endocrine and immune pathways for greater precision and efficacy. With growing research and industry momentum, TSHR is shaping the future of smarter, more targeted thyroid therapies.
2025-10-23
GM-C41979 Dual-Receptor Reporter Cell Line for PD-1–IL-2v Evaluation
Genomeditech has published a white paper on the GM-C41979 Dual-Receptor Reporter Cell Line, detailing its design, validation, and application for PD-1–IL-2v fusion protein evaluation. The report showcases how GM-C41979 integrates PD-1 and IL-2R signaling to provide a high-sensitivity, PD-1-dependent assay system. This publication demonstrates Genomeditech’s commitment to advancing reliable analytical tools for next-generation immuno-oncology drug development.
2025-10-23
CDH17:Roche’s $1.45 Billion Licensing Deal with Hansoh Pharma Spotlights CDH17 ADC Innovation
2025-10-17
FGFR: The Next Breakthrough Target in Cancer Treatment
FGFR2b is rapidly emerging as one of the most promising targets in oncology, driven by new clinical milestones and growing global investment in targeted and antibody-based therapies. Recent breakthroughs highlight how precision modulation of the FGFR pathway could reshape treatment strategies for epithelial tumors and beyond. As innovation accelerates, FGFR2b stands at the forefront of a new wave of cancer therapeutics—where biology, technology, and clinical insight converge.
2025-10-15
GLP-1R: Pfizer to Acquire Metsera and its Next-Generation Obesity Portfolio
2025-09-28
FGF21: The Next Breakthrough in Metabolic Drugs?
In 2025, FGF21 has taken center stage in metabolic drug innovation.

GSK made headlines with a $2B deal for Boston Pharmaceuticals’ efimosfermin alfa. Just months later, Roche answered with its acquisition of 89bio and pegozafermin.

These billion-dollar moves signal a fierce race for FGF21—a once-monthly injectable with potential to regulate metabolism, cut liver fat, reduce inflammation, and reverse fibrosis.

Hailed as the successor to GLP-1, FGF21 is shaping up to be pharma’s next big breakthrough in obesity and metabolic disease.
2025-09-24
2025 WCLC Witnesses: EGFR-Mutant NSCLC Enters the EGFR×HER3 Dual-Target Combination Era
Lung cancer treatment has seen major progress with the rise of targeted therapies, but many patients still face challenges when current options stop working. New scientific advances are now pointing to a different approach—using innovative dual-target and antibody-drug conjugate strategies to block cancer growth more effectively. These next-generation treatments are designed to tackle drug resistance and may offer patients longer-lasting benefits. Together, they signal an important step forward in the search for more reliable and durable solutions for people living with lung cancer.
2025-09-17
The Multifaceted Role of Claudin-1: Regulation of Cancer, Inflammation, and Fibrosis with Therapeutic Implications
Claudin-1 (CLDN1) is emerging as a game-changing target in disease therapy, attracting global attention for its potential to transform the treatment of liver diseases, cancer, and beyond. With innovative therapies already advancing in the clinic, CLDN1 is at the forefront of a new era in precision medicine.
2025-09-10
OX40L:Sanofi’s amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study
2025-09-05
TSLP: The Emerging Key Target in Autoimmune Diseases
2025-09-05
First 1 2 3 4 5 Last
Total 6 Page
Jump
Current position:News > News
classify
News
TSHR: The Core Target in Thyroid Metabolic Regulation and Disease Therapy
The thyroid-stimulating hormone receptor (TSHR) is emerging as a key target in next-generation thyroid and autoimmune disease treatments. Once limited to hormone regulation, TSHR therapies now combine endocrine and immune pathways for greater precision and efficacy. With growing research and industry momentum, TSHR is shaping the future of smarter, more targeted thyroid therapies.
2025-10-23
GM-C41979 Dual-Receptor Reporter Cell Line for PD-1–IL-2v Evaluation
Genomeditech has published a white paper on the GM-C41979 Dual-Receptor Reporter Cell Line, detailing its design, validation, and application for PD-1–IL-2v fusion protein evaluation. The report showcases how GM-C41979 integrates PD-1 and IL-2R signaling to provide a high-sensitivity, PD-1-dependent assay system. This publication demonstrates Genomeditech’s commitment to advancing reliable analytical tools for next-generation immuno-oncology drug development.
2025-10-23
CDH17:Roche’s $1.45 Billion Licensing Deal with Hansoh Pharma Spotlights CDH17 ADC Innovation
2025-10-17
FGFR: The Next Breakthrough Target in Cancer Treatment
FGFR2b is rapidly emerging as one of the most promising targets in oncology, driven by new clinical milestones and growing global investment in targeted and antibody-based therapies. Recent breakthroughs highlight how precision modulation of the FGFR pathway could reshape treatment strategies for epithelial tumors and beyond. As innovation accelerates, FGFR2b stands at the forefront of a new wave of cancer therapeutics—where biology, technology, and clinical insight converge.
2025-10-15
GLP-1R: Pfizer to Acquire Metsera and its Next-Generation Obesity Portfolio
2025-09-28
FGF21: The Next Breakthrough in Metabolic Drugs?
In 2025, FGF21 has taken center stage in metabolic drug innovation.

GSK made headlines with a $2B deal for Boston Pharmaceuticals’ efimosfermin alfa. Just months later, Roche answered with its acquisition of 89bio and pegozafermin.

These billion-dollar moves signal a fierce race for FGF21—a once-monthly injectable with potential to regulate metabolism, cut liver fat, reduce inflammation, and reverse fibrosis.

Hailed as the successor to GLP-1, FGF21 is shaping up to be pharma’s next big breakthrough in obesity and metabolic disease.
2025-09-24
2025 WCLC Witnesses: EGFR-Mutant NSCLC Enters the EGFR×HER3 Dual-Target Combination Era
Lung cancer treatment has seen major progress with the rise of targeted therapies, but many patients still face challenges when current options stop working. New scientific advances are now pointing to a different approach—using innovative dual-target and antibody-drug conjugate strategies to block cancer growth more effectively. These next-generation treatments are designed to tackle drug resistance and may offer patients longer-lasting benefits. Together, they signal an important step forward in the search for more reliable and durable solutions for people living with lung cancer.
2025-09-17
The Multifaceted Role of Claudin-1: Regulation of Cancer, Inflammation, and Fibrosis with Therapeutic Implications
Claudin-1 (CLDN1) is emerging as a game-changing target in disease therapy, attracting global attention for its potential to transform the treatment of liver diseases, cancer, and beyond. With innovative therapies already advancing in the clinic, CLDN1 is at the forefront of a new era in precision medicine.
2025-09-10
OX40L:Sanofi’s amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study
2025-09-05
TSLP: The Emerging Key Target in Autoimmune Diseases
2025-09-05
MORE
Message consultation
reset
submit
Service
Message
Message consultation
reset
submit